Current treatment status-Not currently treated Posts on Medivizor
Navigation Menu

Current treatment status-Not currently treated Posts on Medivizor

Comparing alectinib to ceritinib treatment for ALK-positive non-small-cell lung cancer that failed after crizotinib treatment

Comparing alectinib to ceritinib treatment for ALK-positive non-small-cell lung cancer that failed after crizotinib treatment

Posted by on May 30, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of ceritinib (Zykadia) and alectinib (Alecensa) in patients with ALK-positive non-small-cell lung cancer (NSCLC) who previously had a crizotinib (Xalkori) treatment failure. The data showed that both ceritinib and alectinib were effective in these patients. Some background Non-small-cell lung cancer...

Read More

Comparing PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer.

Comparing PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer.

Posted by on May 30, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer (NSCLC). The data showed that PD-1/PD-L1 inhibitors were safer and more effective than chemotherapy in these patients. Some...

Read More

How effective is rituximab plus gemcitabine and oxaliplatin for patients with refractory/relapsed DLBCL?

How effective is rituximab plus gemcitabine and oxaliplatin for patients with refractory/relapsed DLBCL?

Posted by on May 23, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to evaluate the efficacy and safety of R-GemOx (rituximab, gemcitabine, and oxaliplatin) for the treatment of patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The authors concluded that R-GemOx is an effective treatment regimen in patients ineligible for intensive treatment. Some...

Read More

Copanlisib plus rituximab improves survival in patients with relapsed painless non-Hodgkin lymphoma.

Copanlisib plus rituximab improves survival in patients with relapsed painless non-Hodgkin lymphoma.

Posted by on May 22, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the effectiveness and safety outcomes of copanlisib (Aliqopa) and rituximab (Rituxan) combination for the treatment of patients with relapsed indolent (painless) non-Hodgkin lymphoma (NHL). The data showed that this combination improved the outcomes of these patients with manageable side effects. Some background...

Read More

Adding isatuximab to pomalidomide-dexamethasone therapy for relapsed/refractory multiple myeloma.

Adding isatuximab to pomalidomide-dexamethasone therapy for relapsed/refractory multiple myeloma.

Posted by on May 16, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate the addition of isatuximab (Sarclisa) to pomalidomide (Pomalyst) and dexamethasone (Decadron) therapy for patients with relapsed/refractory (r/r) multiple myeloma (MM). The study found that patients who were given isatuximab had a better outcome. Some background MM is a type of blood cancer...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Melanoma | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including melanoma to examine the safety and effectiveness of experimental drug avapritinib (Ayvakit). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Lung cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including lung cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Breast cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including breast cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

How effective and safe is glofitamab for the treatment of patients with relapsed or refractory B-cell lymphoma?

How effective and safe is glofitamab for the treatment of patients with relapsed or refractory B-cell lymphoma?

Posted by on Apr 25, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to evaluate the safety, optimal dosage, and effectiveness of glofitamab (RO7082859) for the treatment of patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). The authors concluded that glofitamab treatment on its own or in combination with other immunotherapies is safe and effective in these...

Read More

Inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory acute lymphoblastic leukemia

Posted by on Apr 24, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of inotuzumab ozogamicin (InO; Besponsa) and mini-hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 0.5 g/m2  x 4 doses) with or without blinatumomab (Blincyto) in patients with...

Read More

Comparing ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukemia

Comparing ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukemia

Posted by on Apr 11, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of adding ublituximab (TG-1101) to ibrutinib (Imbruvica) treatment for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that adding ublituximab to ibrutinib significantly improved the overall response rate compared to ibrutinib alone...

Read More